Stemline Therapeutics Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- SpaceX shares fall as second lockup period ends
- Supermicro probe finds no senior management link to export violations
- Werewolf Therapeutics sells platform assets to EMD Serono for $33M
Stemline Therapeutics (STML) Misses Q2 EPS by 17c
August 10, 2015 5:08 PM EDTStemline Therapeutics (NASDAQ: STML) reported Q2 EPS of ($0.58), $0.17 worse than the analyst estimate of ($0.41).
For earnings history and earnings-related data on Stemline Therapeutics (STML) click here.
... More